Synergy of Taxol and rhein lysinate associated with the downregulation of ERK activation in lung carcinoma cells

Zhen,Yong‑Zhan; Hu,Gang; Zhao,Yu‑Fang; Yan,Feng; Li,Ran; Gao,Jun‑Ling; Lin,Ya‑Jun

doi:10.3892/ol.2013.1398

Synergy of Taxol and rhein lysinate associated with the downregulation of ERK activation in lung carcinoma cells

Authors:
- Yong‑Zhan Zhen
- Gang Hu
- Yu‑Fang Zhao
- Feng Yan
- Ran Li
- Jun‑Ling Gao
- Ya‑Jun Lin
View Affiliations

Affiliations: Basic Medical College of Hebei United University, Tangshan, Hebei 063000, P.R. China, The Key Laboratory of Geriatrics, Beijing Hospital & Beijing Institute of Geriatrics, Ministry of Health, Beijing 100730, P.R. China
Published online on: June 14, 2013 https://doi.org/10.3892/ol.2013.1398
Pages: 525-528

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In previous studies we observed that rhein lysinate (RHL), a salt of rhein and lysine that is easily dissolved in water, inhibited the growth of tumor cells in breast cancer, ovarian cancer, hepatocellular carcinoma and cervical cancer. The present study aimed to investigate the effects of RHL on H460 and A549 non‑small cell lung cancer (NSCLC) cells using a combination of RHL and Taxol. A 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyl‑tetrazolium bromide (MTT) assay was used to determine the growth inhibition effect of the drugs in the H460 and A549 cells. Cell apoptosis was analyzed by flow cytometry combined with fluorescein‑isothiocyanate‑Annexin Ⅴ/propidium iodide (PI) staining. The expression levels of proteins were detected by western blotting. There was a significant reduction in the proliferation of the NSCLC cell lines treated with a combination of Taxol and RHL. The overall growth inhibition was directly correlated with apoptotic cell death. RHL potentiated Taxol‑induced cell killing by reducing extracellular signal‑regulated kinase (ERK) activity and increasing the levels of cleaved poly(ADP‑ribose) polymerase (PARP) and caspase‑3. Notably, the results for the Bcl‑2 and NF‑κB proteins also showed downregulation in the combined treatment group compared with the single‑agent treatment and the untreated control groups. The present results showed that RHL potentiates the growth inhibition induced by Taxol in NSCLC cells and shoes that this synergy may be associated with the downregulation of ERK activation.

View Figures

View References

1.	Hazra S, Peebles KA, Sharma S, Mao JT and Dubinett SM: The role of PPARgamma in the cyclooxygenase pathway in lung cancer. PPAR Res. 2008:7905682008. View Article : Google Scholar : PubMed/NCBI
2.	Vijayalakshmi R and Krishnamurthy A: Targetable “driver” mutations in non small cell lung cancer. Indian J Surg Oncol. 2:178–188. 2011.
3.	Yuan SF, Chen WJ, Zhu LJ, Zheng WE, Chen H and Xiong JP: Effects of monoclonal antibodies against human stathmin combined with paclitaxel on proliferation of the QG-56 human lung carcinoma cell line. Asian Pac J Cancer Prev. 13:2967–2971. 2012. View Article : Google Scholar : PubMed/NCBI
4.	Kuo PL, Hsu YL, Ng LT and Lin CC: Rhein inhibits the growth and induces the apoptosis of Hep G2 cells. Planta Med. 70:12–16. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Huang Q, Lu G, Shen HM, Chung MC and Ong CN: Anti-cancer properties of anthraquinones from rhubarb. Med Res Rev. 27:609–630. 2007. View Article : Google Scholar : PubMed/NCBI
6.	Lai WW, Yang JS, Lai KC, et al: Rhein induced apoptosis through the endoplasmic reticulum stress, caspase-and mitochondria-dependent pathways in SCC-4 human tongue squamous cancer cells. In Vivo. 23:309–316. 2009.
7.	Ip SW, Weng YS, Lin SY, et al: The role of Ca²⁺ on rhein-induced apoptosis in human cervical cancer Ca Ski cells. Anticancer Res. 27:379–389. 2007.
8.	Lin ML, Chen SS, Lu YC, et al: Rhein induces apoptosis through induction of endoplasmic reticulum stress and Ca²⁺-dependent mitochondrial death pathway in human nasopharyngeal carcinoma cells. Anticancer Res. 27:3313–3322. 2007.PubMed/NCBI
9.	Cichewicz RH, Zhang Y, Seeram NP and Nair MG: Inhibition of human tumor cell proliferation by novel anthraquinones from daylilies. Life Sci. 74:1791–1799. 2004. View Article : Google Scholar : PubMed/NCBI
10.	Floridi A, Gentile PF, Bruno T, et al: Cytotoxic effect of the association of BCNU with rhein or lonidamine on a human glioma cell line. Anticancer Res. 11:789–792. 1991.PubMed/NCBI
11.	Lin YJ and Zhen YS: Rhein lysinate suppresses the growth of breast cancer cells and potentiates the inhibitory effect of Taxol in athymic mice. Anticancer Drugs. 20:65–72. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Lin YJ, Zhen YZ, Shang BY and Zhen YS: Rhein lysinate suppresses the growth of tumor cells and increases the anti-tumor activity of Taxol in mice. Am J Chin Med. 37:923–931. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Lin YJ, Huang YH, Zhen YZ, Liu XJ and Zhen YS: Rhein lysinate induces apoptosis in breast cancer SK-Br-3 cells by inhibiting HER-2 signal pathway. Yao Xue Xue Bao. 43:1099–1105. 2008.(In Chinese).
14.	Zhen YZ, Lin YJ, Gao JL, Zhao YF and Xu AJ: Rhein lysinate inhibits cell growth by modulating various mitogen-activated protein kinases in cervical cancer cells. Oncol Lett. 2:129–133. 2011.PubMed/NCBI
15.	Brognard J and Dennis PA: Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ. 9:893–904. 2002. View Article : Google Scholar : PubMed/NCBI
16.	Lee MW, Kim DS, Min NY and Kim HT: Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin. Int J Cancer. 122:2380–2384. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Ozaki K, Kosugi M, Baba N, et al: Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. Biochem Biophys Res Commun. 391:1610–1615. 2010. View Article : Google Scholar
18.	Lunghi P, Giuliani N, Mazzera L, et al: Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood. 112:2450–2462. 2008. View Article : Google Scholar
19.	Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A and Nagata S: A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 391:43–50. 1998. View Article : Google Scholar : PubMed/NCBI
20.	Wolf BB, Schuler M, Echeverri F and Green DR: Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem. 274:30651–30656. 1999. View Article : Google Scholar : PubMed/NCBI
21.	Fan TJ, Han LH, Cong RS and Liang J: Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai). 37:719–727. 2005. View Article : Google Scholar : PubMed/NCBI
22.	McDonnell TJ, Beham A, Sarkiss M, Andersen MM and Lo P: Importance of the Bcl-2 family in cell death regulation. Experientia. 52:1008–1017. 1996. View Article : Google Scholar : PubMed/NCBI
23.	Reed JC, Miyashita T, Takayama S, et al: BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem. 60:23–32. 1996. View Article : Google Scholar : PubMed/NCBI
24.	Halasova E, Adamkov M, Matakova T, et al: Expression of Ki-67, Bcl-2, Survivin and p53 Proteins in Patients with Pulmonary Carcinoma. Adv Exp Med Biol. 756:15–21. 2013. View Article : Google Scholar : PubMed/NCBI
25.	Arlt A, Gehrz A, Müerköster S, et al: Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 22:3243–3251. 2003. View Article : Google Scholar : PubMed/NCBI
26.	Linardopoulos S: Aurora-A kinase regulates NF-kappaB activity: lessons from combination studies. J BUON. 12(Suppl 1): S67–S70. 2007.PubMed/NCBI
27.	Deng LL, Shao YX, Lv HF, Deng HB and Lv FZ: Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NF-κB survival signaling in lung cancer cells. Neoplasma. 59:18–29. 2012.PubMed/NCBI